ArticleOncoimmunology
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- From Radiation to Immune Response: A Systematic Review of Systemic Immunomodulation in Squamous Cell Head and Neck Cancer.Asian Pacific journal of cancer prevention : APJCP · 2026Pooled it
- Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.Cancer immunology, immunotherapy : CII · 2024Trial
- Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.Journal for immunotherapy of cancer · 2019Trial
- Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.Cancer cell · 2026Article
- Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities.Cells · 2026Review
- Reprogramming chemoimmunotherapy via biomimetic cell membrane- clay platform to amplify prime-boost antitumor immunity.Materials today. Bio · 2026Article
- Differential Metabolic and Transcriptional Responses of PBMCs to Blastocystis sp. Subtypes in Chemotherapy-Treated Colorectal Cancer Patients.Acta parasitologica · 2026Article
- Pre-treatment of cabozantinib prior to hypofractionated radiotherapy increases immunomodulatory effects and tumor size reduction in a 4T1 breast cancer murine model.Scientific reports · 2026Article
- Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Chemoradiotherapy-induced Th17/IL-17 signaling correlates with therapeutic tolerance and early recurrence in cervical carcinoma.BMC molecular and cell biology · 2026Article
- Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.Cancer research · 2026Article
- Immune Predictors of Radiotherapy Outcomes in Cervical Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Association between Urinary-Extracellular-Vesicle-Enriched Proteome Dynamics and Oncological Outcomes Following Concurrent Chemoradiation in Locally Advanced Cervical Cancer.Computational and structural biotechnology journal · 2026Article
- Personalizing DNA Cancer Vaccines.Journal of personalized medicine · 2025Review
- Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Multifunctional Hydrogels for Advanced Cancer Treatment: Diagnostic Imaging and Therapeutic Modalities.Gels (Basel, Switzerland) · 2025Review
- Patients with Cervical Cancer with and without HIV Infection Have Unique T-cell Activation Profiles despite Similar Survival Outcomes after Chemoradiation.Cancer research communications · 2025Article
- Early recovery of leukocyte subsets is associated with favorable progression-free survival in patients with inoperable stage II/III NSCLC after multimodal treatment: a prospective explorative study.Radiation oncology (London, England) · 2025Article
- Development and validation of a deep reinforcement learning algorithm for auto-delineation of organs at risk in cervical cancer radiotherapy.Scientific reports · 2025Article
- Effect of External Beam Radiation Therapy and Brachytherapy on Circulating Myeloid-Derived Suppressor Cell Populations in Patients Treated Definitively for Cervical Cancer.Advances in radiation oncology · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New treatments based on combinations of standard therapeutic modalities and immunotherapy are of potential use, but require a profound understanding of immune modulatory properties of standard therapies. Here, the impact of standard (chemo)radiotherapy on the immune system of cervical cancer patients was evaluated. Thirty patients with cervical cancer were treated with external beam radiation therapy (EBRT), using conventional three-dimensional or intensity modulated radiation therapy without constraints for bone marrow sparing. Serial blood sampling for immunomonitoring was performed before, midway and at 3, 6 and 9 weeks after EBRT to analyze the composition of lymphocyte and myeloid-cell populations, the expression of co-stimulatory molecules, T-cell reactivity and antigen presenting cell (APC) function. Therapy significantly decreased the absolute numbers of circulating leukocytes and lymphocytes. Furthermore, the capacity of the remaining T cells to respond to antigenic or mitogenic stimulation was impaired. During treatment the frequency of both CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.